FDA’s prescription drug user fee rates increased for the upcoming fiscal year despite the agency reducing the human cost of reviewing new drug applications, including Rx-to-OTC switches.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?